While there is some data that TPO-RAs can be safe in the days leading up to splenectomy to achieve platelet numbers to minimize surgical risk, there is an inherent risk for postsplenectomy thrombocytosis that may be augmented by recent TPO-RA therapy. The gene discussed is TPO; the disease is thrombocytosis disease.